Effects of intrarenal infusion of 17-octadecynoic acid on renal antihypertensive mechanisms in anesthetized rabbits.
To characterize the role of cytochrome P450 metabolism of fatty acids in the renal response to increased renal perfusion pressure, we tested the effects of renal arterial infusion of 17-octadecynoic acid (17-ODYA, 450 nmol/min) on renal and systemic hemodynamic, and renal excretory responses to step-wise increases in renal perfusion pressure (RPP) in anesthetized rabbits, using an extracorporeal circuit for renal autoperfusion. Inhibition of cytochrome P450-dependent fatty acid metabolism was estimated by comparing the metabolism of arachidonic acid in microsomes prepared from the kidneys of control and 17-ODYA-treated animals. Step-wise increases in RPP decreased mean arterial pressure, which previous studies have indicated is attributable to the release of a depressor hormone from the renal medulla. Elevations in RPP also increased renal blood flow and glomerular filtration rate, and the absolute and fractional excretions of urine and sodium. Intrarenal infusion of 17-ODYA reduced the metabolism of arachidonic acid to 20-hydroxyeicosatetraenoic acid by 41%, but it did not significantly influence the responses to increased renal perfusion pressure. We conclude that either the responses elicited by increased renal perfusion pressure in anesthetized rabbits do not depend on cytochrome P450-dependent fatty acid metabolism, or that cytochrome P450 activity must be inhibited by more than was achieved in the present study (41%), before functional effects on the response to increased renal perfusion pressure are observed.
Evans
R G
RG
Department of Physiology, Monash University, Clayton, Victoria, Australia. roger.evans@med.monash.edu.au
Day
K H
KH
Roman
R J
RJ
Hopp
K H
KH
Anderson
W P
WP
D000758:Anesthesia; D000803:Angiotensin I / Q000097:blood / Q000187:drug effects; D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D003577:Cytochrome P-450 Enzyme System / Q000502:physiology; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects / Q000502:physiology; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006973:Hypertension / Q000503:physiopathology*; D007261:Infusions, Intra-Arterial; D007668:Kidney / Q000098:blood supply / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D010477:Perfusion; D011312:Pressure; D011817:Rabbits; D012079:Renal Circulation / Q000187:drug effects / Q000502:physiology; D012083:Renin / Q000097:blood / Q000187:drug effects; D012964:Sodium / Q000652:urine
D005231:Fatty Acids, Unsaturated; D016718:Arachidonic Acid; C047008:17-octadecynoic acid; D003577:Cytochrome P-450 Enzyme System; D000803:Angiotensin I; D012964:Sodium; D012083:Renin